Unnamed: 0,title,date,stock,sentiment
885849.0,"Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $134",2020-06-10 10:49:00-04:00,NBIX,neutral
885850.0,"Benzinga's Top Upgrades, Downgrades For June 9, 2020",2020-06-09 09:45:00-04:00,NBIX,positive
885851.0,"Wedbush Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $147",2020-06-09 07:33:00-04:00,NBIX,neutral
885852.0,Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020,2020-06-08 11:03:00-04:00,NBIX,positive
885853.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,NBIX,neutral
885854.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,NBIX,neutral
885855.0,"The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight",2020-05-30 09:25:00-04:00,NBIX,neutral
885856.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,NBIX,positive
885857.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,NBIX,neutral
885858.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,NBIX,neutral
885859.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-19 10:43:00-04:00,NBIX,neutral
885860.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,NBIX,positive
885861.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,NBIX,neutral
885862.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,NBIX,negative
885863.0,Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy,2020-05-12 05:27:00-04:00,NBIX,positive
885864.0,Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy,2020-05-11 16:15:00-04:00,NBIX,positive
885865.0,"Neurocrine Biosciences Announces New Data Published from Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders",2020-05-07 16:30:00-04:00,NBIX,neutral
885866.0,"Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $123",2020-05-07 13:52:00-04:00,NBIX,neutral
885867.0,"Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $105",2020-05-07 11:36:00-04:00,NBIX,neutral
885868.0,"Barclays Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $108",2020-05-07 11:01:00-04:00,NBIX,neutral
885869.0,"Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $120",2020-05-07 08:54:00-04:00,NBIX,negative
885870.0,"Neurocrine Biosciences Q1 EPS $0.390 Misses $0.540 Estimate, Sales $237.100M Beat $223.870M Estimate",2020-05-06 16:27:00-04:00,NBIX,negative
885871.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,NBIX,positive
885872.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,NBIX,neutral
885873.0,"Neurocrine Biosciences shares are trading higher after the company announced that the FDA approved its ONGENTYS as an add on treatment for patients with Parkinson's disease experiencing ""off"" episodes.",2020-04-27 08:58:00-04:00,NBIX,positive
885874.0,Neurocrine Biosciences Announces FDA Approval Of Once-Daily ONGENTYS As An Add-On Treatment For Patients With Parkinson's Disease Experiencing 'Off' Episodes,2020-04-27 07:39:00-04:00,NBIX,positive
885875.0,FDA Site Shows Approval For Neurocrine Biosciences' Ongentys,2020-04-27 07:23:00-04:00,NBIX,positive
885876.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,NBIX,negative
885877.0,"Oppenheimer Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $130",2020-04-13 09:21:00-04:00,NBIX,negative
885878.0,"Voyager Therapeutics Reports It, Collaborator Neurocrine Biosciences Temporarily Paused Screening Of New Patients In RESTORE-1 Trial; Will Resume When Cos. Can Determine Screening Will Be Safety, Effective",2020-04-03 08:33:00-04:00,NBIX,positive
885879.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2020-03-31 17:15:00-04:00,NBIX,neutral
885880.0,10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades,2020-03-17 17:13:00-04:00,NBIX,neutral
885881.0,"Benzinga's Top Upgrades, Downgrades For March 6, 2020",2020-03-06 09:39:00-05:00,NBIX,positive
885882.0,"Citigroup Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces $124 Price Target",2020-03-06 05:01:00-05:00,NBIX,neutral
885883.0,"William Blair Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces $116 Price Target",2020-02-24 10:21:00-05:00,NBIX,neutral
885884.0,"Mizuho Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces $107 Price Target",2020-02-06 05:14:00-05:00,NBIX,neutral
885885.0,"Mizuho Initiates Coverage On Pfizer, Evolus, Karuna Therapeutics With Buy Ratings, Neurocrine Biosciences, Sage Therapeutics With Neutrals",2020-02-05 16:48:00-05:00,NBIX,neutral
885886.0,"H.C. Wainwright Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $125",2020-02-05 07:15:00-05:00,NBIX,neutral
885887.0,"Neurocrine Biosciences Q4 EPS $0.35 Misses $0.75 Estimate, Sales $237.9M Beat $230.94M Estimate",2020-02-04 16:04:00-05:00,NBIX,negative
885888.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,NBIX,negative
885889.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,NBIX,neutral
885890.0,"Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $121",2020-01-17 08:28:00-05:00,NBIX,negative
885891.0,"Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $132",2020-01-13 09:10:00-05:00,NBIX,neutral
885892.0,Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy,2020-01-10 05:58:00-05:00,NBIX,positive
885893.0,"Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $120",2019-12-17 09:15:00-05:00,NBIX,negative
885894.0,"Credit Suisse Downgrades Neurocrine Biosciences to Neutral, Announces $110 Price Target",2019-12-13 07:13:00-05:00,NBIX,positive
885895.0,Xenon Pharmaceuticals 13D Shows Neurocrine Biosciences Holds 5.4% Stake In Co.,2019-12-11 16:18:00-05:00,NBIX,neutral
885896.0,"Neurocrine Biosciences Shares Fall At Open, Down 6%, As Traders Circulate Word Of Negative Report By Aurelius Value",2019-12-11 09:32:00-05:00,NBIX,neutral
885897.0,Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at AES 2019,2019-12-07 14:56:00-05:00,NBIX,neutral
885898.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,NBIX,positive
885899.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,NBIX,neutral
885900.0,Xenon to Receive $50M Upfront Payment From Neurocrine Biosciences for the Rights to Xenon's XEN901,2019-12-02 07:31:00-05:00,NBIX,neutral
885901.0,Stocks That Hit 52-Week Highs On Friday,2019-11-29 10:28:00-05:00,NBIX,neutral
885902.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,NBIX,neutral
885903.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,NBIX,positive
885904.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,NBIX,neutral
885905.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,NBIX,neutral
885906.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,NBIX,neutral
885907.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,NBIX,neutral
885908.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,NBIX,neutral
885909.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,NBIX,neutral
885910.0,Stocks That Hit 52-Week Highs On Monday,2019-11-11 10:15:00-05:00,NBIX,neutral
885911.0,"Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $122",2019-11-05 11:30:00-05:00,NBIX,neutral
885912.0,"Neurocrine Biosciences Q3 EPS $0.56 Misses $0.64 Estimate, Sales $222.1M Beat $211.63M Estimate",2019-11-04 16:02:00-05:00,NBIX,negative
885913.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,NBIX,neutral
885914.0,Neurocrine Biosciences Late Friday Presented Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress,2019-10-07 08:50:00-04:00,NBIX,neutral
885915.0,Neurocrine Biosciences Reports Will Present Data Showing Long-Term Effectiveness of INGREZZA® in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress,2019-10-01 16:11:00-04:00,NBIX,neutral
885916.0,Neurocrine Biosciences To Present Data Analyses Demonstrating The Long-Term Effectiveness Of INGREZZA In Patients With Tardive Dyskinesia At The 2019 Annual Psych Congress  Oct. 3-6,2019-10-01 16:02:00-04:00,NBIX,neutral
885917.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,NBIX,neutral
885918.0,"UPDATE: Baird's Skorney, When Asked If Neurocrine Shares Rebound Is Related To Traders Circulating Data From A Clinicaltrial.gov Study, Says 'I Don't Think So. The Rebound Seems Pretty Nominal And In-line With The Rest Of The Sector.'",2019-09-25 12:20:00-04:00,NBIX,positive
885919.0,"Neurocrine Shares Earlier Spiked 1.8% Following Trader Circulation Of ClinicalTrials.gov Doc, Price Soon After Pared Gains; Baird's Brian Skorney Tells Benzinga 'This Study Really Shouldn't Have Any Impact On Outlook For NBIX'",2019-09-25 12:20:00-04:00,NBIX,positive
885920.0,"Neurocrine Biosciences Shares Rebound From Session Low As Traders Circulate ClinicalTrials.gov Study Record Detail Doc For 'Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease (KINECT-HD)'",2019-09-25 10:53:00-04:00,NBIX,positive
885921.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,NBIX,negative
885922.0,"Neurocrine Biosciences Highlights Will Present Data On INGREZZA For Tardive Dyskinesia, Opicapone, VY-AADC For Parkinson's At International Congress of Parkinson's Disease and Movement Disorders",2019-09-17 16:21:00-04:00,NBIX,neutral
885923.0,"Benzinga's Top Upgrades, Downgrades For August 7, 2019",2019-08-07 09:48:00-04:00,NBIX,positive
885924.0,"RBC Capital Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces $118 Price Target",2019-08-07 08:32:00-04:00,NBIX,neutral
885925.0,AbbVie Submits New Drug Application FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women,2019-08-05 08:35:00-04:00,NBIX,neutral
885926.0,29 Healthcare Stocks Moving In Friday's After-Market Session,2019-08-02 20:51:00-04:00,NBIX,neutral
885927.0,28 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-01 04:20:00-04:00,NBIX,neutral
885928.0,80 Biggest Movers From Yesterday,2019-07-31 05:28:00-04:00,NBIX,neutral
885929.0,58 Stocks Moving In Tuesday's Mid-Day Session,2019-07-30 12:39:00-04:00,NBIX,neutral
885930.0,Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-07-30 11:29:00-04:00,NBIX,positive
885931.0,"Credit Suisse Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $110",2019-07-30 09:59:00-04:00,NBIX,positive
885932.0,33 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-30 09:16:00-04:00,NBIX,neutral
885933.0,"Piper Jaffray Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $111",2019-07-30 08:34:00-04:00,NBIX,negative
885934.0,42 Stocks Moving In Tuesday's Pre-Market Session,2019-07-30 08:14:00-04:00,NBIX,neutral
885935.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,NBIX,positive
885936.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,NBIX,neutral
885937.0,"Neurocrine Biosciences Q2 EPS $0.54 May Not Compare To $0.11 Estimate, Sales $183.58M Beat $163.14M Estimate",2019-07-29 16:24:00-04:00,NBIX,neutral
885938.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,NBIX,negative
885939.0,"The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug",2019-07-11 06:17:00-04:00,NBIX,neutral
885940.0,Neurocrine Biosciences Announces FDA Acceptance Of New Drug Application For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease,2019-07-10 16:12:00-04:00,NBIX,positive
885941.0,"Neurocrine Biosciences Highlights Will Present Data On INGREZZA, Opicapone At World Congress on Parkinson's Disease and Related Disorders",2019-06-11 16:01:00-04:00,NBIX,neutral
885942.0,"Guggenheim Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces $88 Price Target",2019-06-05 06:38:00-04:00,NBIX,neutral
885943.0,"Credit Suisse Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock with Outperform Rating, Announces $95 Price Target",2019-05-21 07:08:00-04:00,NBIX,positive
885944.0,"Hearing Credit Suisse Initiated Coverage On Neurocrine Biosciences With Outperform Rating, $95 Price Target",2019-05-20 17:22:00-04:00,NBIX,positive
885945.0,Neurocrine Biosciences Highlights Presentation Of New Data From RE-KINECT Showing The Effect Of Involuntary Movements On Patient Quality of Life,2019-05-20 08:08:00-04:00,NBIX,neutral
885946.0,Neurocrine Biosciences Highlights Presentation Of New Quality-of-Life Data Analysis from RE-KINECT At American Psychiatric Association Annual Meeting,2019-05-16 17:06:00-04:00,NBIX,neutral
885947.0,Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug,2019-05-14 11:14:00-04:00,NBIX,negative
885948.0,"Neurocrine Biosciences, Voyager Therapeutics Announce Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with Parkinson's Disease",2019-05-05 09:29:00-04:00,NBIX,positive
885949.0,Neurocrine Biosciences Announces Phase III Data Showa Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations,2019-05-05 09:27:00-04:00,NBIX,positive
885950.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,NBIX,negative
885951.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,NBIX,positive
885952.0,Neurocrine Biosciences shares are trading lower after the company reported lower-than-expected Q1 EPS results.,2019-04-29 17:47:00-04:00,NBIX,neutral
885953.0,"Neurocrine Biosciences Q1 EPS $(1.12) Misses $(0.92) Estimate, Sales $138.403M Beat $137.03M Estimate",2019-04-29 16:39:00-04:00,NBIX,negative
885954.0,Neurocrine Biosciences Option Alert: May 17 $90 Calls at the Ask: 1000 @ $0.85 vs 4814 OI; Earnings 4/29 After Close Ref=$77.44,2019-04-29 14:58:00-04:00,NBIX,positive
885955.0,Neurocrine Biosciences Says Express Scripts National Preferred Currently Accounts For Less Than One Percent Of Ingrezza Product Revenue; Continues To Engage With Express Scripts,2019-04-26 14:00:00-04:00,NBIX,positive
885956.0,"Express Scripts Published Updated 2019 National Preferred Formulary Exclusions List That Will Exclude Ingrezza (Valbenazine); Exclusing Is Effective July 1, 2019",2019-04-26 13:59:00-04:00,NBIX,positive
885957.0,Neurocrine Biosciences Option Alert: Jun 21 $80 Calls Sweep (2) near the Bid: 2000 @ $3.101 vs 13 OI; Earnings 4/29 After Close Ref=$74.24,2019-04-26 12:29:00-04:00,NBIX,positive
885958.0,Neurocrine Biosciences Shares Fall As Express Scripts Reportedly Excluded Its Drug From Formulary,2019-04-26 11:46:00-04:00,NBIX,negative
885959.0,6 Biggest Price Target Changes For Monday,2019-04-22 10:04:00-04:00,NBIX,neutral
885960.0,"Benzinga's Top Upgrades, Downgrades For April 22, 2019",2019-04-22 08:55:00-04:00,NBIX,positive
885961.0,"JP Morgan Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $106",2019-04-22 06:41:00-04:00,NBIX,neutral
885962.0,Evercore ISI Group Initiates Coverage On Neurocrine Biosciences with Outperform Rating,2019-04-12 07:27:00-04:00,NBIX,neutral
885963.0,Neurocrine Biosciences And Voyager Therapeutics Announce Publication Of Phase 1b Trial Results Of VY-AADC For Parkinson's Disease In The Annals Of Neurology,2019-03-28 16:16:00-04:00,NBIX,neutral
885964.0,Neurocrine Biosciences Reports Interim Results From Phase II Study Of NBI-74788 In Adults With Classic Congenital Adrenal Hyperplasia; Results Showed At LEast 50% Reduction From Baseline,2019-03-12 08:05:00-04:00,NBIX,neutral
885965.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,NBIX,neutral
885966.0,"Neurocrine Biosciences Sees FY19 Sales Milestones Under AbbVie Deal $20M; Ongoing SG&A, R&D Expenses Expected $550M-$600M",2019-02-05 16:37:00-05:00,NBIX,neutral
885967.0,"Neurocrine Biosciences Q4 EPS $0.19 Beats $0.15 Estimate, Sales $131.492M Beat $128.11M Estimate",2019-02-05 16:36:00-05:00,NBIX,neutral
885968.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,NBIX,positive
885969.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,NBIX,neutral
885970.0,"Neurocrine Biosciences And Voyager Therapeutics Form Strategic Development And Commercialization Collaboration For Parkinson's Disease And Friedreich's Ataxia; Voyager Receives $165M Upfront, Up To $1.7B In Milestones",2019-01-29 07:12:00-05:00,NBIX,neutral
885971.0,Needham Downgrades Neurocrine Biosciences to Hold,2019-01-24 07:51:00-05:00,NBIX,neutral
885972.0,"JP Morgan Downgrades Neurocrine Biosciences to Neutral, Raises Price Target to $100",2019-01-23 08:10:00-05:00,NBIX,positive
885973.0,Neurocrine Biosciences Highlights Analysis Of Its INGREZZA Capsules In The Journal Of Affective Disorders,2019-01-16 16:03:00-05:00,NBIX,neutral
885974.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,NBIX,neutral
885975.0,42 Stocks Moving In Monday's Mid-Day Session,2019-01-07 13:49:00-05:00,NBIX,neutral
885976.0,Neurocrine Biosciences shares are trading higher after the company announced it expects Q4 net product sales to have doubled since last year.,2019-01-07 10:41:00-05:00,NBIX,positive
885977.0,Neurocrine Biosciences Sees Q4 Net Product Sales $130M vs $64.5M YoY; Sees FY 2018 Net Product Sales $409M vs $116.6M YoY,2019-01-06 19:58:00-05:00,NBIX,neutral
885978.0,"Goldman Sachs Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces $103 Price Target",2018-12-13 09:29:00-05:00,NBIX,neutral
885979.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,NBIX,neutral
885980.0,Mid-Afternoon Market Update: Sparton Climbs On Acquisition News; Synergy Pharmaceuticals Shares Slide,2018-12-12 14:39:00-05:00,NBIX,positive
885981.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-12-12 12:33:00-05:00,NBIX,neutral
885982.0,Mid-Day Market Update: NASDAQ Rises 2%; Neurocrine Biosciences Shares Plunge,2018-12-12 12:04:00-05:00,NBIX,positive
885983.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018",2018-12-12 11:47:00-05:00,NBIX,negative
885984.0,Mid-Morning Market Update: Markets Open Higher; Vera Bradley Misses Q3 Estimates,2018-12-12 10:18:00-05:00,NBIX,negative
885985.0,Neurocrine Biosciences are trading steeply lower after the company announced a Phase IIb study did not meet its primary endpoint in Tourette's Syndrome patients.,2018-12-12 08:50:00-05:00,NBIX,negative
885986.0,"Neurocrine Biosciences Resume Trade, Down 25.8%",2018-12-12 08:00:00-05:00,NBIX,neutral
885987.0,Neurocrine Biosciences Shares To Resume Trade At 8:00 a.m. ET,2018-12-12 07:35:00-05:00,NBIX,positive
885988.0,Neurocrine Biosciences Announces Topline Data From Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint In Pediatric Patients with Tourette Syndrome,2018-12-12 07:30:00-05:00,NBIX,neutral
885989.0,"Neurocrine Biosciences Shares Halted, News Pending",2018-12-12 07:25:00-05:00,NBIX,positive
885990.0,Neurocrine Biosciences Option Alert: Dec 21 $100 Calls Sweep (2) near the Ask: 938 @ $1.101 vs 546 OI; Ref=$86.39,2018-12-06 10:46:00-05:00,NBIX,positive
885991.0,"Benzinga's Top Upgrades, Downgrades For November 21, 2018",2018-11-21 08:53:00-05:00,NBIX,positive
885992.0,"Canaccord Genuity Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces $111 Price Target",2018-11-21 08:17:00-05:00,NBIX,neutral
885993.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,NBIX,positive
885994.0,76 Biggest Movers From Yesterday,2018-11-15 04:20:00-05:00,NBIX,neutral
885995.0,AbbVie Reports Presented Phase 3 Data Showing Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress,2018-11-14 17:36:00-05:00,NBIX,neutral
885996.0,"Leerink Swann Initiates Coverage On Neurocrine Biosciences with Market Perform Rating, Announces $110 Price Target",2018-11-13 08:46:00-05:00,NBIX,neutral
885997.0,"Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $135",2018-11-06 12:39:00-05:00,NBIX,negative
885998.0,24 Stocks Moving In Tuesday's Pre-Market Session,2018-11-06 08:07:00-05:00,NBIX,neutral
885999.0,"Neurocrine Biosciences Q3 EPS $0.52 Beats $0.46 Estimate, Sales $151.757M Miss $151.83M Estimate",2018-11-05 16:36:00-05:00,NBIX,negative
886000.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,NBIX,neutral
886001.0,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",2018-10-26 16:22:00-04:00,NBIX,positive
886002.0,'A New Way To Treat The Brain': Stanford University Scientists Launch Cannabis Pharma Company,2018-10-26 13:14:00-04:00,NBIX,positive
886003.0,Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines To Treat Central Nervous System Disorders,2018-10-09 16:02:00-04:00,NBIX,positive
886004.0,"Neurocrine Biosciences Says Will Present New Long-Term Data Analyses On INGREZZA At International Congress of Parkinson's Disease and Movement Disorders (MDS) in Hong Kong, Oct. 5-9, 2018",2018-10-01 16:03:00-04:00,NBIX,neutral
886005.0,"Stifel Nicolaus Maintains Buy on Neurocrine Biosciences, Raises Price Target to $142",2018-09-20 07:14:00-04:00,NBIX,neutral
886006.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,NBIX,neutral
886007.0,"A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others",2018-09-10 16:10:00-04:00,NBIX,neutral
886008.0,"Benzinga's Top Upgrades, Downgrades For September 10, 2018",2018-09-10 09:31:00-04:00,NBIX,positive
886009.0,"Morgan Stanley Initiates Coverage On Neurocrine Biosciences with Overweight Rating, Announces $145 Price Target",2018-09-10 07:28:00-04:00,NBIX,negative
886010.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,NBIX,neutral
886011.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,NBIX,neutral
886012.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,NBIX,positive
886013.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,NBIX,neutral
886014.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,NBIX,neutral
886015.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,NBIX,neutral
886016.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,NBIX,neutral
886017.0,"Benzinga's Top Upgrades, Downgrades For August 23, 2018",2018-08-23 09:21:00-04:00,NBIX,positive
886018.0,"Cantor Fitzgerald Initiates Coverage On Neurocrine Biosciences with Overweight Rating, Announces $150 Price Target",2018-08-23 07:09:00-04:00,NBIX,negative
886019.0,Neurocrine Biosciences Will Present INGREZZA Data At 2018 World Congress On Parkinson's August 19-22,2018-08-15 16:11:00-04:00,NBIX,neutral
886020.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,NBIX,neutral
886021.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,NBIX,negative
886022.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,NBIX,neutral
886023.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,NBIX,neutral
886024.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,NBIX,neutral
886025.0,4 Reasons Behind Stifel's Neurocrine Bull Thesis,2018-08-07 11:07:00-04:00,NBIX,neutral
886026.0,"Benzinga's Top Upgrades, Downgrades For August 7, 2018",2018-08-07 09:03:00-04:00,NBIX,positive
886027.0,"Stifel Nicolaus Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces $137 Price Target",2018-08-07 07:21:00-04:00,NBIX,neutral
886028.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,NBIX,neutral
886029.0,"Stocks Which Set New 52-Week High Yesterday, August 1st",2018-08-02 10:56:00-04:00,NBIX,neutral
886030.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,NBIX,positive
886031.0,66 Biggest Movers From Yesterday,2018-08-02 05:50:00-04:00,NBIX,neutral
886032.0,"Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $135",2018-08-01 14:03:00-04:00,NBIX,negative
886033.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,NBIX,negative
886034.0,"Neurocrine Biosciences Q2 EPS $(0.07) Beats $(0.17) Estimate, Sales $96.905M Beat $84.11M Estimate",2018-07-31 16:20:00-04:00,NBIX,neutral
886035.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,NBIX,neutral
886036.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,NBIX,neutral
886037.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,NBIX,negative
886038.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,NBIX,neutral
886039.0,"Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $122",2018-07-25 08:38:00-04:00,NBIX,neutral
886040.0,Neurocrine Biosciences 8-K Highlights FDA Approval Of AbbVie's ORILISSA; Co. To Receive $40M Event-Based Payment Made By AbbVie,2018-07-24 14:36:00-04:00,NBIX,positive
886041.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,NBIX,neutral
886042.0,Neurocrine Biosciences Option Alert: Jul 20 $110 Calls at the Ask: 500 @ $1.0 vs 382 OI; Earnings 8/2 After Close [est] Ref=$101.905,2018-07-06 11:13:00-04:00,NBIX,positive
886043.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,NBIX,neutral
886044.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2018-06-30 18:05:00-04:00,NBIX,neutral
886045.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,NBIX,positive
886046.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,NBIX,positive
886047.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,NBIX,neutral
886048.0,"UPDATE: Neurocrine Highlights 'New Data from KINECT 4 Study Show Long-Term Treatment with INGREZZA® (valbenazine) Capsules Provided Sustained, Clinically Meaningful Improvement in Tardive Dyskinesia and was Well-Tolerated'",2018-05-08 14:01:00-04:00,NBIX,positive
886049.0,UPDATE: Neurocrine Says Nearly 28% Of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia,2018-05-08 14:01:00-04:00,NBIX,neutral
886050.0,Neurocrine Biosciences Reports Presentation Of New Quality Of Life Data From RE-KINECT Study Of Possible Tardive Dyskinesia In Patients Treated with Antipsychotics,2018-05-08 14:00:00-04:00,NBIX,neutral
886051.0,"Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $100.00",2018-05-01 09:47:00-04:00,NBIX,neutral
886052.0,"JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $103.00",2018-05-01 09:21:00-04:00,NBIX,neutral
886053.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,NBIX,neutral
886054.0,Neurocrine Biosciences Raises FY18 Operating Expenses Guidaance From $365-$395M to $395M-$420M,2018-04-30 16:04:00-04:00,NBIX,neutral
886055.0,"Neurocrine Biosciences Q1 EPS $(0.47) Misses $(0.31) Est., Sales $71.1M Beats $63.79M Est.",2018-04-30 16:03:00-04:00,NBIX,negative
886056.0,AbbVie and Neurocrine Biosciences Reports That The FDA Requires Extended Time For Review Of Additional Info In New Drug Application;  Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain,2018-04-10 08:19:00-04:00,NBIX,negative
886057.0,Abbvie and Neurocrine Biosciences Notified by the FDA that Additional Time is Required to Review Additional Information,2018-04-10 08:18:00-04:00,NBIX,neutral
886058.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,NBIX,neutral
886059.0,"13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies",2018-02-15 10:41:00-05:00,NBIX,positive
886060.0,Neurocrine Biosciences Will File NDA For Opicapone in 1H19,2018-02-14 16:36:00-05:00,NBIX,neutral
886061.0,"JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises price target to $100.00",2018-02-14 08:23:00-05:00,NBIX,neutral
886062.0,"Neurocrine Biosciences Reports Q4 EPS $0.07 vs $0.18 Est., Sales $94.5M vs $87M Est.",2018-02-13 16:07:00-05:00,NBIX,neutral
886063.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-01-23 08:02:00-05:00,NBIX,neutral
886064.0,"Neurocrine Bioscience Option Alert: Dec, 2018 $70 Puts at the Ask: 750 @ $8.801 vs 0 OI; Earnings 2/13 After Close [est] Ref=$77.87",2018-01-08 15:21:00-05:00,NBIX,positive
886065.0,"Neurocrine Biosciences Saturday Announced CMO Christopher O'Briend Retriring, Eiry Roberts To Assume Position",2018-01-08 09:33:00-05:00,NBIX,neutral
886066.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,NBIX,positive
886067.0,Neurocrine Biosciences Reports Preliminary Q4 Sales ~$94M vs $76.09M Est; FY 2017 Sales ~$161M vs $143.17M Est,2018-01-07 13:59:00-05:00,NBIX,neutral
886068.0,Neurocrine Bioscience Option Alert: Feb 16 $60 Puts Sweep (11) at the Bid: 600 @ $1.0 vs 229 OI; Ref=$70.33,2017-12-18 10:42:00-05:00,NBIX,positive
886069.0,"Neurocrine Biosciences Presents New Long-Term Data From KINECT 4 Phase III Open-Label Study, Shows INGREZZA Improved Symptoms Through 48 Wks",2017-12-04 16:14:00-05:00,NBIX,positive
886070.0,Neurocrine Biosciences Names Matt Abernethy CFO,2017-11-20 16:01:00-05:00,NBIX,neutral
886071.0,Neurocrine Reports Long-Term Results Evaluating INGREZZA for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry,2017-11-14 13:37:00-05:00,NBIX,neutral
886072.0,66 Biggest Movers From Yesterday,2017-11-03 04:49:00-04:00,NBIX,neutral
886073.0,Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch,2017-11-02 13:48:00-04:00,NBIX,neutral
886074.0,52 Stocks Moving In Thursday's Mid-Day Session,2017-11-02 12:29:00-04:00,NBIX,neutral
886075.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-11-02 08:25:00-04:00,NBIX,neutral
886076.0,"Neurocrine Q3 EPS $(0.13) vs $(0.49) Est., Sales $60.77M vs 29.86M Est., May Not Compare",2017-11-01 17:10:00-04:00,NBIX,neutral
886077.0,AbbVie Announces 'Positive' Phase 3 Extension Study Data For Elagolix,2017-11-01 12:02:00-04:00,NBIX,neutral
886078.0,Neurocrine STarts Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome,2017-10-25 16:40:00-04:00,NBIX,neutral
886079.0,Neurocrine Biosciences Granted FDA Orphan Drug Designation For Valbenazine,2017-10-23 16:57:00-04:00,NBIX,positive
886080.0,"A Peek Into The Markets: U.S. Stock Futures Flat Ahead Of Fed Speakers, Economic Data",2017-10-05 07:19:00-04:00,NBIX,neutral
886081.0,Neurocrine Biosciences Reports FDA Approval Of 80mg INGREZZA Capsules For Treatment Of Adults With TD,2017-10-05 07:10:00-04:00,NBIX,positive
886082.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,NBIX,neutral
886083.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,NBIX,neutral
886084.0,"Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments",2017-08-25 12:03:00-04:00,NBIX,positive
886085.0,"Neurocrine Biosciences Reports Q2 EPS $(0.68) vs $(0.66) Est., Sales $6.3M vs $660K Est.",2017-08-03 17:14:00-04:00,NBIX,neutral
886086.0,Neurocine Bioscienes Submitted a Supplemental NDA to the FDA for Ingrezza,2017-07-05 07:04:00-04:00,NBIX,neutral
886087.0,Neurocrine Biosciences Spikes to High of $47.34 on Volume,2017-06-27 13:28:00-04:00,NBIX,neutral
886088.0,Reminder: Neurocrine Biosciences Phase II Ingrezza Study Results Expected By End Of May,2017-05-31 09:36:00-04:00,NBIX,neutral
886089.0,"Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out",2017-05-24 15:34:00-04:00,NBIX,negative
886090.0,15 Biggest Mid-Day Losers For Wednesday,2017-05-24 12:59:00-04:00,NBIX,negative
886091.0,"BMO on Neurocrine Biosciences: 'Buy on the Weakness'; Maintains Outperform Rating, $75 Price Target",2017-05-24 09:11:00-04:00,NBIX,neutral
886092.0,Neurocrine Reports Phase II Results of INGREZZA for Treatment of Tourette Syndrome: Did Not Meet Primary Endpoint,2017-05-23 16:03:00-04:00,NBIX,neutral
886093.0,"Companies Holding Shareholder Meetings Today Include: Morgan Stanley, Neurocrine Biosciences, DeVry Education, Twitter, Summer Infant, & Royal Carribean Cruises",2017-05-22 09:00:00-04:00,NBIX,neutral
886094.0,"Bank Of America Health Care Conference Continues Today; Presenters Include Celgene, Ionis, Neurocrine Biosciences, Cigna, GW Pharma, Allergan, Ironwood Pharma, Tenet Healthcare, Civitas Solutions, & Amgen",2017-05-17 09:03:00-04:00,NBIX,positive
886095.0,Neurocrine Biosciences Reports Q1 EPS $(0.90) vs $(0.74) Est.,2017-05-09 16:05:00-04:00,NBIX,neutral
886096.0,"Benzinga's Top Upgrades, Downgrades For May 5, 2017",2017-05-05 09:30:00-04:00,NBIX,positive
886097.0,"Bank of America Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces $70.00 Price Target",2017-05-05 08:00:00-04:00,NBIX,neutral
886098.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,NBIX,positive
886099.0,Neurocrine Announces INGREZZA Long-Term Safety and Efficacy Data to be Presented at the AAN 2017,2017-04-21 06:04:00-04:00,NBIX,positive
886100.0,The Market In 5 Minutes,2017-04-13 09:20:00-04:00,NBIX,neutral
886101.0,"Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva",2017-04-12 13:40:00-04:00,NBIX,negative
886102.0,Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside,2017-04-12 12:57:00-04:00,NBIX,positive
886103.0,11 Biggest Mid-Day Gainers For Wednesday,2017-04-12 12:38:00-04:00,NBIX,neutral
886104.0,Martin Shkreli on Facebook Posts '$NBIX juicy short',2017-04-12 11:28:00-04:00,NBIX,neutral
886105.0,Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval,2017-04-12 10:18:00-04:00,NBIX,positive
886106.0,19 Stocks Moving In Wednesday's Pre-Market Session,2017-04-12 09:10:00-04:00,NBIX,neutral
886107.0,"Hearing BMO Out Positive On Neurocrine, Says Positive Ingrezza Label, Coupled With Other Catalysts, Opens Pathway For Greater Than $100/Share Stock",2017-04-12 08:30:00-04:00,NBIX,positive
886108.0,Neurocrine Biosciences +24.1% Preamarket @ $51.50; Co Announced FDA Approval of INGREZZA on Tuesday,2017-04-12 06:32:00-04:00,NBIX,positive
886109.0,"CNBC's Meg Tirrell Recently Tweets '$NBIX says it ""will announce pricing concurrent with launch and the deployment of its sales reps in May""'",2017-04-11 17:48:00-04:00,NBIX,neutral
886110.0,"Neurocrine Biosciences Shares Resume, Now Up ~14%",2017-04-11 17:25:00-04:00,NBIX,positive
886111.0,Adam Feuerstein Tweets: $NBIX says no black box safety warning for Ingrezza. That's an added positive in competitive fight against $TEVA.,2017-04-11 17:01:00-04:00,NBIX,positive
886112.0,Neurocrine Shares to Resume Trade at 5:25 p.m. EDT,2017-04-11 17:00:00-04:00,NBIX,positive
886113.0,"UPDATE: Neurocrine To Host Investor Conf. Call, Webcast Scheduled For Today At 5:30pm ET",2017-04-11 16:54:00-04:00,NBIX,neutral
886114.0,Neurocrine Reports FDA Approval of INGREZZA TM,2017-04-11 16:53:00-04:00,NBIX,positive
886115.0,Neurocrine Biosciences Halted News Pending,2017-04-11 16:47:00-04:00,NBIX,neutral
886116.0,Neurocrine Biosciences Shares Up Nearly 2% Over Last Few Mins; BZ NOTE: Co. Has Discussion with FDA Panel/PDUFA Date Today,2017-04-11 14:00:00-04:00,NBIX,positive
886117.0,Neurocrine Biosciences INGREZZA Has FDA PDUFA Date Today,2017-04-11 08:11:00-04:00,NBIX,neutral
886118.0,"Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive",2017-03-24 15:18:00-04:00,NBIX,positive
886119.0,Neurocrine Reports Kinect 3 Phase 3 Study of INGREZZA for Treatment of Tardive Dyskinesia Shows 'significant and meaningful reduction in symptoms',2017-03-21 09:01:00-04:00,NBIX,positive
886120.0,Neurocrine Reports American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM for the Treatment of Tardive Dyskinesia,2017-03-21 08:59:00-04:00,NBIX,positive
886121.0,Neurocrine Biosciences Reports Q4 EPS $(0.51) vs $(0.56) Est.,2017-02-14 16:37:00-05:00,NBIX,neutral
886122.0,"Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone, Nerocrine Will Make Upfront Payment Of $30M, Fund All Development To Get FDA Approval",2017-02-09 16:26:00-05:00,NBIX,positive
886123.0,15 Biggest Mid-Day Gainers For Friday,2017-01-27 12:58:00-05:00,NBIX,neutral
886124.0,"Benzinga's Top Upgrades, Downgrades For January 27, 2017",2017-01-27 09:24:00-05:00,NBIX,positive
886125.0,Oppenheimer Upgrades Neurocrine Biosciences To Outperform,2017-01-27 07:33:00-05:00,NBIX,neutral
886126.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-01-18 08:25:00-05:00,NBIX,neutral
886127.0,Neurocrine Biosciences Shares Down 5% Premarket Following News Late Tues. Showing Pre-Specified Primary Endpoint at Week 8 Not Met,2017-01-18 07:38:00-05:00,NBIX,positive
886128.0,7 Biotech Catalysts Remaining In January,2017-01-13 14:08:00-05:00,NBIX,neutral
886129.0,15 Biggest Mid-Day Gainers For Friday,2017-01-06 12:51:00-05:00,NBIX,neutral
886130.0,Neurocrince Biosciences Announces David Alexandre Gros COO,2017-01-06 08:32:00-05:00,NBIX,neutral
886131.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-06 08:25:00-05:00,NBIX,neutral
886132.0,Neurocrine Provides Update on FDA Advisory Committee for INGREZZA for the Treatment of Tardive Dyskinesia,2017-01-05 16:04:00-05:00,NBIX,neutral
886133.0,"Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'",2017-01-05 11:48:00-05:00,NBIX,positive
886134.0,Neurocrine Biosciences  CFO Timothy P. Coughlin to Step Down,2016-12-21 16:03:00-05:00,NBIX,neutral
886135.0,"BMO Capital Healthcare Conf. Takes Place Today; Presenters Include Neurocrine Biosciences, Ionis Pharmaceuticals, Horizon Pharma, And Intercept Pharmaceuticals",2016-12-14 08:41:00-05:00,NBIX,neutral
886136.0,10 Stocks With Lowest Close In Three Weeks,2016-12-09 05:34:00-05:00,NBIX,negative
886137.0,Neurocrine Biosciences Shares Down 4.54% Middday On Above Average Volume,2016-12-08 12:00:00-05:00,NBIX,positive
886138.0,Martin Shkreli Tweets: $NBIX definitely not a long in my brief (and dangerous) view. company did a good job rescuing itself on this drug but hard to see it sell,2016-12-08 11:58:00-05:00,NBIX,positive
886139.0,Neurocrine Biosciences Shares Down 4.42% Midday On Above Average Volume,2016-12-08 11:54:00-05:00,NBIX,positive
886140.0,Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA New Drug Application for the Treatment of Tardive Dyskinesia,2016-11-29 16:16:00-05:00,NBIX,neutral
886141.0,6 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-11-23 08:00:00-05:00,NBIX,neutral
886142.0,"Oppenheimer Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock at Perform, Announces $55.00 Target",2016-11-22 08:20:00-05:00,NBIX,neutral
886143.0,"Deutsche Bank Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock at Buy",2016-11-03 06:05:00-04:00,NBIX,neutral
886144.0,Neurocrine Biosciences Reports Q3 EPS $(0.43) vs. Est. $(0.57),2016-11-02 16:45:00-04:00,NBIX,neutral
886145.0,"AbbVie Reports Elagolix Shows Superiority To Placebo In Reducing Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis, FDA NDA Anticipated in 2017",2016-10-19 09:02:00-04:00,NBIX,negative
886146.0,Abbvie/Neurocrine Biosciences Phase 3 Elagolix Trial Data Expected To Be Presented At American Society For Reproductive Medicine Mtg,2016-10-19 08:51:00-04:00,NBIX,neutral
886147.0,Benzinga's Top Initiations,2016-10-18 09:28:00-04:00,NBIX,positive
886148.0,"Needham Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock at Buy, Announces $62.00",2016-10-18 07:26:00-04:00,NBIX,neutral
886149.0,Neurocrine Announces INGREZZA NDA for Treatment of Tardive Dyskinesia has been Accepted for Priority Review by FDA,2016-10-11 06:58:00-04:00,NBIX,positive
886150.0,Neurocrine Biosciences New Drug Application Accepted for Review by FDA,2016-10-11 06:57:00-04:00,NBIX,positive
886151.0,"Leerink Swann Assumes Neurocrine Biosciences at Outperform, Announces $70.00 PT",2016-10-04 07:13:00-04:00,NBIX,neutral
886152.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,NBIX,neutral
886153.0,Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine,2016-08-31 16:02:00-04:00,NBIX,positive
886154.0,Neurocrine Submits NDA for Valbenazine for Treatment of Tardive Dyskinesia,2016-08-29 16:02:00-04:00,NBIX,neutral
886155.0,Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome,2016-07-28 16:48:00-04:00,NBIX,negative
886156.0,Benzinga's Top Initiations,2016-06-29 09:30:00-04:00,NBIX,positive
886157.0,"H.C. Wainwright Initiates Coverage on Neurocrine Biosciences at Buy, Announces $80.00 PT",2016-06-29 07:08:00-04:00,NBIX,neutral
886158.0,"Neurocrine Biosciences' Board Member, Thomas Mitchell Retires",2016-05-20 09:01:00-04:00,NBIX,neutral
886159.0,Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting,2016-05-06 08:32:00-04:00,NBIX,neutral
886160.0,"Neurocrine Biosciences Reports Q1 EPS $(0.22) Vs Est $(0.29), $15M Vs Est $15.43M",2016-05-05 16:36:00-04:00,NBIX,neutral
886161.0,Option Alert: NBIX Jun16 50.0 Calls Sweep: 1239 @  ASK  $3.00: 1239 traded vs 1354 OI:  Earnings 5/5  $46.05 Ref,2016-04-19 10:54:00-04:00,NBIX,positive
886162.0,BMO Capital Initiates Coverage on Neurocrine Biosciences at Outperform,2016-04-07 06:29:00-04:00,NBIX,neutral
886163.0,Neurocrine Bioscience +6% After-Hours @$38.50,2016-03-03 16:10:00-05:00,NBIX,neutral
886164.0,Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016,2016-03-02 08:32:00-05:00,NBIX,positive
886165.0,Neurocrine Biosciences Reports Q4 EPS $(0.34) vs $(0.32) Est.; Sees FY16 Cash Burn ~$135M-$145M,2016-02-11 16:39:00-05:00,NBIX,neutral
886166.0,Mid-Day Market Update: Akamai Technologies Surges On Earnings Beat; KapStone Paper and Packaging Shares Drop,2016-02-10 12:04:00-05:00,NBIX,neutral
886167.0,Neurocrine Begins Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome,2016-02-02 08:31:00-05:00,NBIX,negative
886168.0,AbbVie Initiates Enrollment For Phase 3 Clinical Program For Elagolix Patients With Uterine Fibroids,2016-01-28 06:58:00-05:00,NBIX,neutral
886169.0,Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome,2015-12-16 16:06:00-05:00,NBIX,positive
886170.0,Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of Contract - 8-K Filings,2015-12-02 17:07:00-05:00,NBIX,negative
886171.0,Neurocrine Biosciences Reports Expansion of its Clinical Pipeline,2015-11-04 08:05:00-05:00,NBIX,neutral
886172.0,Neurocrine Reports Q3 Loss of $0.40/Share vs Loss $0.25/Share Est.,2015-10-29 16:30:00-04:00,NBIX,negative
886173.0,Neurocrine Bioscience Reports Initiation of Phase I Study of NBI-98854 in Adults with Tourette Syndrome,2015-10-20 08:32:00-04:00,NBIX,neutral
886174.0,Hearing PiperJaffray Raising Neurocrine Bioscience PT To $96 From $86,2015-10-08 10:52:00-04:00,NBIX,neutral
886175.0,Benzinga's Volume Movers,2015-10-08 10:28:00-04:00,NBIX,neutral
886176.0,Morning Market Gainers,2015-10-08 09:43:00-04:00,NBIX,neutral
886177.0,Benzinga's Top #PreMarket Gainers,2015-10-08 08:11:00-04:00,NBIX,positive
886178.0,Neurocrine Biosciences +28% Premarket as Phase III Kinect Trial of NBI-98854 Met Primary Endpoint,2015-10-08 07:26:00-04:00,NBIX,neutral
886179.0,US Stock Futures Down Ahead Of Fed Minutes,2015-10-08 06:50:00-04:00,NBIX,neutral
886180.0,UPDATE: Neurocrine Says Phase III Kinect Trial of NBI-98854 Met Primary Endpoint; Submission of NDA Planned for '16,2015-10-08 06:32:00-04:00,NBIX,neutral
886181.0,Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia,2015-10-08 06:31:00-04:00,NBIX,positive
886182.0,Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors,2015-09-30 16:31:00-04:00,NBIX,neutral
886183.0,AbbVie Offers Plans to Proceed to Phase 3 Evaluation of Elagolix,2015-09-16 09:01:00-04:00,NBIX,neutral
886184.0,Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors,2015-09-03 08:33:00-04:00,NBIX,neutral
886185.0,"Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health",2015-08-25 14:59:00-04:00,NBIX,neutral
886186.0,What Should Biotech Investors Do Now?,2015-08-25 14:47:00-04:00,NBIX,neutral
886187.0,Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study,2015-08-13 08:00:00-04:00,NBIX,neutral
886188.0,Neurocrine Biosciences Reports Q2 EPS $(0.28) vs. Est. $(0.29),2015-07-29 17:38:00-04:00,NBIX,neutral
886189.0,Leerink Swann Assumes Neurocrine Biosciences at Outperform,2015-07-21 08:12:00-04:00,NBIX,neutral
886190.0,Morning Market Losers,2015-06-09 09:56:00-04:00,NBIX,negative
886191.0,Benzinga's Top #PreMarket Losers,2015-06-09 08:17:00-04:00,NBIX,negative
886192.0,"Aeropostale, SouFun, Cyberark Led Monday's After-Hours Movers",2015-06-09 06:21:00-04:00,NBIX,neutral
886193.0,Neurocrine Biosciences Shares Fall 14% After-Hours on News Company Halted Clinical Studies of NBI-77860,2015-06-08 16:31:00-04:00,NBIX,positive
886194.0,UPDATE: Neurocrine Reports Suspension of Two Planned Clinical Studies of Co.'s CRF Antagonist NBI-77860,2015-06-08 16:29:00-04:00,NBIX,negative
886195.0,Neurocrine Biosciences Gives Update on NBI-77860 Program for Congenital Adrenal Hyperplasia,2015-06-08 16:28:00-04:00,NBIX,neutral
886196.0,"Neurocrine Biosciences, Inc. Reports Eric Benevich As Chief Commercial Officer",2015-06-02 08:11:00-04:00,NBIX,neutral
886197.0,Neurocrine Biosciences Reports Q1 Loss of $0.01/Share,2015-04-30 07:20:00-04:00,NBIX,negative
886198.0,"Neurocrine Biosciences, Mitsubishi Tanabe Pharma Announce Agreement to Develop NBI-98854 in Japan, Other Asian Markets",2015-04-01 04:47:00-04:00,NBIX,positive
886199.0,JP Morgan Initiates Neurocrine Biosciences With Overweight,2015-03-19 09:18:00-04:00,NBIX,neutral
886200.0,Benzinga's Top Initiations,2015-03-19 08:56:00-04:00,NBIX,positive
886201.0,"JP Morgan Initiates Coverage on Neurocrine Biosciences at Overweight, Announces $54.00 PT",2015-03-19 06:07:00-04:00,NBIX,neutral
886202.0,Barclays Expands Coverage To 7 New Biotech Stocks,2015-03-04 11:29:00-05:00,NBIX,positive
886203.0,Stocks Hitting 52-Week Highs,2015-03-04 10:15:00-05:00,NBIX,neutral
886204.0,"Barclays Initiates Coverage on Neurocrine Biosciences at Overweight, Announces $60.00 PT",2015-03-04 06:32:00-05:00,NBIX,negative
886205.0,"UPDATE: Neurocrine Biosciences Prices 6.94M Shares at $36/Share, Expecting Gross Proceeds $250M",2015-02-19 07:08:00-05:00,NBIX,negative
886206.0,Neurocrine Biosciences Prices 6.944M Share Offering @$36.00/Share,2015-02-19 07:07:00-05:00,NBIX,positive
886207.0,Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals,2015-02-18 10:15:00-05:00,NBIX,positive
886208.0,Neurocrine Biosciences Announces Proposed $225M Common Stock Offering,2015-02-17 16:18:00-05:00,NBIX,neutral
886209.0,Neurocrine Biosciences Reports Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO '15,2015-01-20 08:08:00-05:00,NBIX,neutral
886210.0,Press Release Confirms Neurocrine Biosciences Granted Orphan Drug Status for NBI-77860,2015-01-16 14:32:00-05:00,NBIX,positive
886211.0,Stocks Hitting 52-Week Highs,2015-01-15 10:25:00-05:00,NBIX,neutral
886212.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,NBIX,neutral
886213.0,Shares Of Neurocrine Move Higher Following Deutsche Bank Price Target Raise to $35.00/share,2015-01-08 15:16:00-05:00,NBIX,positive
886214.0,Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates,2015-01-08 11:39:00-05:00,NBIX,positive
886215.0,Benzinga's Volume Movers,2015-01-08 10:33:00-05:00,NBIX,neutral
886216.0,Stocks Hitting 52-Week Highs,2015-01-08 10:22:00-05:00,NBIX,neutral
886217.0,Morning Market Gainers,2015-01-08 09:45:00-05:00,NBIX,neutral
886218.0,"Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning",2015-01-08 09:00:00-05:00,NBIX,neutral
886219.0,Neurocrine Biosciences Shares Rise 20% Premarket Following Announcement of Positive Top-Line Results From Phase 3 Study of Elagolix,2015-01-08 08:16:00-05:00,NBIX,positive
886220.0,Benzinga's Top #PreMarket Gainers,2015-01-08 08:12:00-05:00,NBIX,positive
886221.0,UPDATE: AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix,2015-01-08 08:02:00-05:00,NBIX,positive
886222.0,What Investors Expect From Neurocrine Biosciences' Next Drug Announcement,2015-01-02 14:53:00-05:00,NBIX,neutral
886223.0,Neurocrine Biosciences Announces Expansion of its Clinical Pipeline,2014-12-10 08:06:00-05:00,NBIX,neutral
886224.0,Neurocrine Biosciences Reports Expansion of Clinical Pipeline,2014-12-10 08:02:00-05:00,NBIX,neutral
886225.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,NBIX,neutral
886226.0,Neurocrine Biosciences Appoints Darin Lippoldt As Chief Legal Officer ,2014-11-04 07:36:00-05:00,NBIX,positive
886227.0,"Neurocrine Biosciences, Inc. Reports Q3 EPS of $(0.21), Inline",2014-11-03 16:11:00-05:00,NBIX,neutral
886228.0,Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia ,2014-10-30 07:33:00-04:00,NBIX,neutral
886229.0,"UPDATE: Neurocrine Reports Topline Efficacy Data During 2H of 2015, Expecting to File NDA in 2H of 2016",2014-10-20 16:09:00-04:00,NBIX,neutral
886230.0,Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 ,2014-10-20 16:06:00-04:00,NBIX,negative
886231.0,Neurocrine Initiates Tourette Syndrome Clinical Trial,2014-10-02 16:03:00-04:00,NBIX,neutral
886232.0,"Neurocrine Biosciences, Inc. Reports Q1 EPS of $(0.17) vs $(0.19) Est",2014-04-30 16:03:00-04:00,NBIX,neutral
886233.0,"US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data",2014-02-27 07:18:00-05:00,NBIX,neutral
886234.0,Neurocrine Biosciences Prices 8M Share Offering at $17.75/Share,2014-02-27 05:39:00-05:00,NBIX,positive
886235.0,Neurocrine Files KINECT 1 Study Reanalysis Results in SEC Filing,2014-02-25 16:13:00-05:00,NBIX,neutral
886236.0,Neurocrine Biosciences Announces 7M Share Offering of Common Stock ,2014-02-25 16:01:00-05:00,NBIX,positive
886237.0,"CORRECTION: Neurocrine Biosciences, Inc. Reports Q4 Loss of $0.16/Share, Sales $700K; Sees FY14 Net Loss of $0.82-0.90/Share",2014-02-06 16:42:00-05:00,NBIX,negative
886238.0,UPDATE: Neurocrine Says NBI-98854 Showed Meaningful Reduction,2014-01-09 16:34:00-05:00,NBIX,positive
886239.0,Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854,2014-01-09 16:32:00-05:00,NBIX,positive
886240.0,UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation,2014-01-08 08:32:00-05:00,NBIX,positive
886241.0,Benzinga's Top #PreMarket Losers,2014-01-08 08:20:00-05:00,NBIX,negative
886242.0,"Nomura Initiates Coverage on Neurocrine Biosciences, Inc. at Buy, Announces $23.00 PT",2014-01-08 07:46:00-05:00,NBIX,neutral
886243.0,"Morgan Stanley Downgrades Neurocrine Biosciences, Inc. to Equal-weight, Raises to $16.00",2014-01-08 06:37:00-05:00,NBIX,neutral
886244.0,Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report,2014-01-07 15:43:00-05:00,NBIX,neutral
886245.0,Neurocrine Biosciences CEO to Appear CNBC StreetSigns Between 2:00 PM-3:00 PM,2014-01-07 13:48:00-05:00,NBIX,neutral
886246.0,Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates,2014-01-07 11:38:00-05:00,NBIX,positive
886247.0,Benzinga's Volume Movers,2014-01-07 11:03:00-05:00,NBIX,neutral
886248.0,Morning Market Movers ,2014-01-07 10:07:00-05:00,NBIX,neutral
886249.0,"Deutsche Bank Maintains Buy on Neurocrine Biosciences, Inc., Raises PT to $25.00",2014-01-07 08:46:00-05:00,NBIX,neutral
886250.0,Benzinga's Top #PreMarket Gainers,2014-01-07 08:07:00-05:00,NBIX,positive
886251.0,Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study,2014-01-06 16:02:00-05:00,NBIX,positive
886252.0,"Piper Jaffray Initiates Coverage on Neurocrine Biosciences, Inc. at Overweight, Announces $17.00 PT",2013-12-19 07:50:00-05:00,NBIX,negative
886253.0,"Neurocrine Biosciences, Inc. Reports Q3 EPS of $(0.17) vs $(0.20) Est; Revenue of $729.0K vs $790.0K Est",2013-10-29 16:47:00-04:00,NBIX,neutral
886254.0,Kilroy Realty Acquires Premier Del Mar Office Campus for Approximately $126M,2013-09-19 19:20:00-04:00,NBIX,neutral
886255.0,"Market Wrap For Tuesday, September 10: Once Again, China Moves Markets Higher",2013-09-10 16:22:00-04:00,NBIX,neutral
886256.0,"Mid-Afternoon Market Update: Apple Releases Two New iPhones, SolarCity Rallies on New Contract",2013-09-10 15:46:00-04:00,NBIX,neutral
886257.0,Mid-Day Market Update: Five Below Shares Gain On Upbeat Results; Urban Outfitters Tumbles,2013-09-10 12:59:00-04:00,NBIX,positive
886258.0,Mid-Morning Market Update: Markets Rise; McDonald's Global Same-Store Sales Increase 1.9%,2013-09-10 11:04:00-04:00,NBIX,positive
886259.0,Morning Market Losers ,2013-09-10 10:24:00-04:00,NBIX,negative
886260.0,Benzinga's Top Pre-Market Losers,2013-09-10 08:14:00-04:00,NBIX,negative
886261.0,"Deutsche Bank Maintains Buy on Neurocrine Biosciences, Inc., Lowers PT to $18.00",2013-09-10 07:37:00-04:00,NBIX,negative
886262.0,"Neurocrine Announces Negative Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia; Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET",2013-09-09 16:03:00-04:00,NBIX,negative
886263.0,Neurocrine Biosciences Spikes Higher,2013-09-03 14:36:00-04:00,NBIX,neutral
886264.0,UPDATE: Deutsche Bank Raises PT on Neurocrine Biosciences Ahead of Key Catalysts,2013-08-29 08:55:00-04:00,NBIX,neutral
886265.0,"Cowen & Company Upgrades Neurocrine Biosciences, Inc. to Outperform, Announces $20.00 PT",2013-08-21 09:24:00-04:00,NBIX,neutral
886266.0,"Neurocrine Biosciences, Inc. Reports Q2 EPS of $(0.18) vs $(0.19) Est; Revenue of $730.0K vs $760.0K Est",2013-07-25 16:56:00-04:00,NBIX,neutral
886267.0,UPDATE: Oppenheimer Initiates Coverage on Neurocrine Biosciences on Potential Elagolix Success,2013-06-18 17:40:00-04:00,NBIX,positive
886268.0,"Oppenheimer Initiates Coverage on Neurocrine Biosciences, Inc. at Outperform, Announces $16.00 PT",2013-06-18 16:16:00-04:00,NBIX,neutral
886269.0,Hearing Chatter of Positive Seeking Alpha Report on Neurocrine Biosciences,2013-05-09 13:50:00-04:00,NBIX,positive
886270.0,"Neurocrine Biosciences, Inc. Reports Q1 EPS of $(0.18), Inline; Revenue of $730.0K vs $1.12M Est",2013-05-02 16:26:00-04:00,NBIX,neutral
886271.0,"Neurocrine Biosciences Says Elagolix Enters Phase IIB for Uterine Fibroids, Says Endometriosis Phase III on Track",2013-05-02 16:21:00-04:00,NBIX,neutral
886272.0,Neurocrine Biosciences Commences Phase IIB Study of Elagolix in Uterine Fibroids,2013-03-27 07:20:00-04:00,NBIX,neutral
886273.0,"UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report",2013-02-11 11:40:00-05:00,NBIX,neutral
886274.0,Stocks Hitting 52-Week Highs,2013-02-11 10:30:00-05:00,NBIX,neutral
886275.0,"Jefferies Maintains Buy on Neurocrine Biosciences, Inc., Raises PT to $14.00",2013-02-11 08:10:00-05:00,NBIX,neutral
886276.0,"Neurocrine Biosciences, Inc. Reports Q4 EPS of $0.14, Up 600% YOY; Revenue of $21.90M; Guides FY13",2013-02-08 07:55:00-05:00,NBIX,neutral
886277.0,"Earnings Scheduled For February 8, 2013",2013-02-08 02:31:00-05:00,NBIX,neutral
886278.0,"Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further",2013-02-05 15:57:00-05:00,NBIX,neutral
886279.0,"Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, $11 Price Target, Neurocrine Biosciences with a Buy and $13 PT, Repros Therapeutics with Buy, $26 PT",2013-02-05 10:12:00-05:00,NBIX,neutral
886280.0,Neurocrine Biosciences Files $150M Stock Shelf,2012-11-20 16:52:00-05:00,NBIX,neutral
886281.0,Neurocrine Biosciences Reports Q3 EPS $-0.05 vs $-0.05 Est; Revenues $16.8M vs $15.8M Est,2012-10-31 16:25:00-04:00,NBIX,neutral
886282.0,UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight  on Asset Quality  ,2012-10-04 14:39:00-04:00,NBIX,neutral
886283.0,"Morgan Stanley Initiates Coverage on Neurocrine Biosciences at Overweight, Announces PT of $12",2012-10-03 16:07:00-04:00,NBIX,negative
886284.0,Neurocrine Announces Start of Phase 2B Study of Vmat2 Inhibitor,2012-10-01 16:06:00-04:00,NBIX,negative
886285.0,Neurocrine Biosciences Reports Q2 EPS $-0.01 vs $-0.03 Est; Revenues $10.6M vs $11.00M Est,2012-07-31 16:19:00-04:00,NBIX,neutral
886286.0,Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis ,2012-06-05 08:01:00-04:00,NBIX,neutral
886288.0,Neurocrine Biosciences Reports Q1  Revenues $11.3M vs $10.84M Est,2012-05-02 16:29:00-04:00,NBIX,neutral
886289.0,Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012 ,2012-03-27 08:02:00-04:00,NBIX,neutral
886290.0,UPDATE: Neurocrine Data From One Site Was Removed Due To The Inconsistent And Incorrect Application Of The Efficacy Assessment Protocol.,2012-03-26 16:02:00-04:00,NBIX,neutral
886291.0,Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia ,2012-03-26 16:01:00-04:00,NBIX,negative
886292.0,"Deutsche Bank Initiates Coverage on Neurocrine Biosciences at Buy, Announces PT of $15",2012-03-16 06:22:00-04:00,NBIX,neutral
886293.0,"UPDATE: Deutsche Bank Initiates Buy, $15 PT on Neurocrine",2012-03-16 06:17:00-04:00,NBIX,neutral
886294.0,Neurocrine Biosciences Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares  ,2012-01-30 16:00:00-05:00,NBIX,positive
886295.0,Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854 ,2012-01-25 08:31:00-05:00,NBIX,positive
886296.0,Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share ,2012-01-19 09:11:00-05:00,NBIX,positive
886297.0,Neurocrine Biosciences Announces Proposed Public Offering of Common Stock; No Amount given   ,2012-01-18 16:01:00-05:00,NBIX,negative
886298.0,Neurocrine Biosciences Spiking Higher on Heavy Volume,2011-11-04 10:53:00-04:00,NBIX,neutral
886299.0,Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?,2011-11-02 08:46:00-04:00,NBIX,neutral
886300.0,Jefferies Has Buy on Neurocrine Bio After Earnings,2011-11-01 07:50:00-04:00,NBIX,neutral
886301.0,Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement ,2011-10-04 16:05:00-04:00,NBIX,positive
886302.0,Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial,2011-09-19 16:00:00-04:00,NBIX,neutral
886303.0,Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids ,2011-09-13 08:31:00-04:00,NBIX,neutral
886304.0,Benzinga's Top Pre-Market Losers,2011-08-23 08:13:00-04:00,NBIX,negative
886305.0,Calls Purchased on Neurocrine Biosciences,2011-08-11 12:27:00-04:00,NBIX,neutral
886306.0,Neurocrine Biosciences Reports Q2 EPS $0.04 vs $0.05 Est; Revenues $12.2M vs $13.21M Est	,2011-07-28 16:28:00-04:00,NBIX,neutral
886307.0,Jefferies Maintains Buy on Neurocrine Biosciences,2011-06-24 07:21:00-04:00,NBIX,neutral
886308.0,Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor,2011-06-23 08:35:00-04:00,NBIX,negative
886309.0,Technical Trading Summary 6/7/2011,2011-06-07 17:40:00-04:00,NBIX,neutral
886310.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,NBIX,positive
886311.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,NBIX,negative
886312.0,Jefferies Has Buy Rating On Neurocrine Bio. (NBIX),2011-04-06 07:43:00-04:00,NBIX,neutral
886313.0,Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor ,2011-04-05 09:11:00-04:00,NBIX,positive
886314.0,Jefferies Has Buy Rating On Neurocrine Bio. (NBIX),2011-03-28 07:31:00-04:00,NBIX,neutral
886315.0,Piper Jaffray Maintains Overweight on Neurocrine Biosciences (NBIX),2011-03-25 09:52:00-04:00,NBIX,negative
886316.0,Neurocrine Biosciences Up 7.6% On Earnings Beat (NBIX),2011-02-11 14:42:00-05:00,NBIX,neutral
886317.0,Hapoalim Sees Strong Upside In Neurocrine Biosciences (NBIX),2011-02-11 11:27:00-05:00,NBIX,positive
886318.0,Neurocrine Biosciences: Marching to 52 Week High (NBIX),2010-12-22 12:25:00-05:00,NBIX,neutral
886319.0,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share ,2010-12-22 09:49:00-05:00,NBIX,positive
886320.0,Best Biotech CEO of 2010 Is...,2010-12-15 11:51:00-05:00,NBIX,positive
886321.0,Biotech's Brighter Corners,2010-12-08 12:45:00-05:00,NBIX,positive
886322.0,Vote for the Best Biotech CEO of 2010,2010-12-08 07:02:00-05:00,NBIX,positive
886323.0,5 Drug Stock Winners of 2010,2010-12-07 07:04:00-05:00,NBIX,positive
886324.0,ETFs For Biotech M&A Mania,2010-12-06 14:05:00-05:00,NBIX,neutral
886325.0,Jefferies Comments On Neurocrine Bio's Daisy PETAL Study,2010-11-23 10:11:00-05:00,NBIX,neutral
886326.0,"Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Jacobs Engineering, Ford, Kellogg and Honda Motor Co.    - Press Releases",2010-11-02 11:00:00-04:00,NBIX,neutral
886327.0,Neurocrine Biosciences Reports Third Quarter 2010 Results: EPS of $0.06,2010-10-28 16:32:00-04:00,NBIX,neutral
886328.0,Neurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials,2010-10-18 08:11:00-04:00,NBIX,neutral
886329.0,Neurocrine Biosciences Falls on Corticotropin Data (NBIX),2010-09-14 16:32:00-04:00,NBIX,neutral
886330.0,"Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Big 5 Sporting Goods, Aetna, CVS Caremark and Express Scripts    - Press Releases",2010-08-03 09:10:00-04:00,NBIX,neutral
886331.0,Neurocrine Biosciences (NBIX) - Bull of the Day,2010-08-03 02:51:00-04:00,NBIX,neutral
886332.0,Hapoalim Securities Reiterates Buy Rating on Neurocrine Biosciences (NBIX),2010-07-29 13:55:00-04:00,NBIX,positive
886333.0,Neurocrine Biosciences Reports Second Quarter 2010 Results,2010-07-28 16:24:00-04:00,NBIX,neutral
886334.0,"Early Volume Plays Among Those Valued Below $10 (FCH, ABT, NBIX, DSCO)",2010-06-17 10:48:00-04:00,NBIX,positive
886335.0,"Benzinga’s Top Pre-Market Gainers (FSLR, CRUS, NBIX, NVDA)",2010-06-17 08:51:00-04:00,NBIX,positive
886336.0,"Stocks Hitting 52-Week Highs (SMTS, CRUS, NBIX, ARUN)",2010-06-16 14:17:00-04:00,NBIX,neutral
886337.0,"Mid-Day Market Movers (TLCR, PDO, XFN, NBIX)",2010-06-16 10:41:00-04:00,NBIX,neutral
886338.0,"Benzinga’s Top Pre-Market Gainers (SMTS, NBIX, IMMU, CLNE)",2010-06-16 08:40:00-04:00,NBIX,positive
886339.0,"Mid-Day Market Movers (CJBK, NBIX, MELA, HAFC)",2010-05-26 11:38:00-04:00,NBIX,neutral
886340.0,"Mid-Day Market Movers On The NASDAQ (NBIX, PLBC, RDCM, LJPC)",2010-05-25 13:53:00-04:00,NBIX,neutral
886341.0,"Early Volume Plays Among Those Valued Below $10 (S, NBIX, AIB, IRE, LYG, NBG)",2010-05-25 10:39:00-04:00,NBIX,positive
886342.0,Neurocrine Bioscienes (NBIX) All Set To Search For Higher Top,2010-05-25 10:33:00-04:00,NBIX,positive
886343.0,Piper Jaffray Upgrades Neurocrine Biosciences to Overweight (NBIX),2010-05-25 09:22:00-04:00,NBIX,negative
886344.0,"Benzinga’s Top Pre-Market Gainers (NBIX, BSPM, TEVA, HOKU)",2010-05-25 09:01:00-04:00,NBIX,positive
886345.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,NBIX,positive
886346.0,"Potential Volume Plays For March 5, 2010 (CNXT, BRCD, ZANE, NBIX, YMI)",2010-03-05 14:07:00-05:00,NBIX,positive
886347.0,"Benzinga’s Top Pre-Market Losers (MRVL, CNXT, NBIX, SOLF, MENT)",2010-03-05 08:31:00-05:00,NBIX,negative
886348.0,"Stocks To Watch (OMTR,CKR,NBIX,PPG,RMBS,C)",2009-09-16 05:43:00-04:00,NBIX,neutral
